But there's also the matter of outright greed. As repugnant as the Turing price-gouging case may have been (it involved an even-older medication used by a smaller group of people), the outrageous price of the EpiPen has affected far more Americans. Nor is this the first time Mylan has put profits ahead of the public good. Two years ago, the company pulled off a tax inversion — acquiring a smaller foreign company and then shipping its headquarters overseas to avoid paying its share of U.S. taxes. The company remains in Canonsburg, Pa., but for tax purposes, its corporate headquarters is in the Netherlands.